Frontage Announces Proposal by a Consortium for Privatization and Asset Restructuring to Unlock Value and Fuel Strategic Growth
EXTON, PENNSYLVANIA / HONG KONG, November 9, 2026 — Frontage Holdings Corporation (“Frontage”) (HKEX: 1521) today announced a proposal by an investor consortium for (i) the privatization of Frontage from the HKEX, and (ii) a subsequent asset restructuring (together, the “Transaction”). For further details regarding the Transaction, please refer to Frontage’s announcement dated November 9, 2026, available on the website of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and on www.frontagelab.com.
As part of the asset restructuring, Frontage’s business is expected to be divided among an investor consortium, comprising Charles River Laboratories, Tigermed, and Dr. Song Li, Frontage’s Chairman. Specifically, upon completion of the restructuring, (i) Frontage’s Exton, Pennsylvania-based bioanalysis and drug metabolism and pharmacokinetics (DMPK) business is expected to be owned and operated by Charles River Laboratories, (ii) Frontage’s business in the People’s Republic of China (the “PRC”) and the business currently owned and operated by Acme Bioscience, Inc. and/or its subsidiaries are expected to be owned and operated by Tigermed, and (iii) Frontage’s remaining business outside of the PRC including bioanalysis and DMPK outside of Exton Pennsylvania is expected to be owned and operated by Dr. Song Li.
“The Transaction aims to unlock shareholder value and position Frontage for future long-term growth.” Dr. Wentao Zhang and Dr. Zhongping Lin, Executive Directors and Co-CEOs of Frontage, commented, “The proposed privatization will allow management to redeploy resources directly into core operations, while the subsequent restructuring of Frontage’s business will empower local business units to navigate evolving regulatory frameworks, market conditions and client dynamics with greater focus and agility.”
The Transaction remains subject to shareholder and regulatory approvals, as well as customary closing conditions. Until the Transaction closes, Frontage will continue its business operations in the ordinary course. The same Frontage team will continue to support our clients on all ongoing projects, studies, and contracts with the same quality and timelines.
Further details regarding the Transaction, including the expected schedule for the shareholder meetings, will be set out in a shareholder document to be dispatched to Frontage shareholders in due course.
Wilson Sonsini Goodrich & Rosati is serving as the legal advisor to Frontage in this Transaction and Gram Capital Limited has been appointed as an independent financial advisor to the independent board committee of Frontage.
About Frontage
Frontage is a global Contract Research, Development, and Manufacturing Organization (CRO/CDMO) offering fully integrated, science-driven solutions across the drug discovery and development journey. Founded in 2001 and headquartered in Exton, Pennsylvania, with multiple facilities across the U.S., Canada, Europe and China, Frontage provides a broad range of capabilities – from drug discovery, API synthesis, DMPK, and safety & toxicology to formulation development and manufacturing, CMC analytical, clinical trials, bioanalytical and central lab services.